On November 18, Legend Biotech rose 5.25% in Regular Trading, trading at $16.92 per share, with turnover of $3.4256 million.
The clearest catalyst behind the move was a newly disclosed insider purchase: director Peter Salovey acquired 20,000 ordinary shares for about $183,250, lifting his direct beneficial ownership to 75,096 shares.
The buying came after a volatile post-earnings stretch. Legend Biotech reported third-quarter net profit of $51.7 million, reversing a year-earlier loss, while CARVYKTI net sales rose 36% year over year to about $710 million. However, quarterly revenue of $359.5 million was slightly below market expectations, prompting a series of analyst target cuts and an Evercore ISI downgrade to In Line with a $20 price target. Against that backdrop, the director purchase appeared to improve near-term confidence and supported a technical rebound in the shares.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments